TY - JOUR
T1 - A pharmacogenomic evaluation of migraine therapy
AU - Johnson, Matthew P.
AU - Fernandez, Francesca
AU - Colson, Natalie J.
AU - Griffiths, Lyn R.
PY - 2007/8/1
Y1 - 2007/8/1
N2 - Migraine is a common idiopathic primary headache disorder with significant mental, physical and social health implications. Accompanying an intense unilateral pulsating head pain other characteristic migraine symptoms include nausea, emesis, phonophobia, photophobia and in - 20 - 30% of migraine cases, neurologic disturbances associated with the aura phase. Although selective serotonin (5-HT) receptor agonists (i.e., 5-HT1B/1D) are successful in alleviating migrainous symptoms in ≤ 70% of known sufferers, for the remaining 30%, additional migraine abortive medications remain unsuccessful, not tested or yet to be identified. Genetic characterization of the migrainous disorder is making steady progress with an increasing number of genomic susceptibility loci now identified on chromosomes 1q, 4q, 5q, 6p, 11q, 14q, 15q, 17p, 18q, 19p and Xq. The 4q, 5q, 17p and 18q loci involve endophenotypic susceptibility regions for various migrainous symptoms. In an effort to develop individualized pharmacotherapeutics, the identification of these migraine endophenotypic loci may well be the catalyst needed to aid in this goal. In this review the authors discuss the present treatment of migraine, known genomic susceptibility regions and results from migraine (genetic) association studies. The authors also discuss pharmacogenomc considerations for more individualized migraine prophylactic treatments.
AB - Migraine is a common idiopathic primary headache disorder with significant mental, physical and social health implications. Accompanying an intense unilateral pulsating head pain other characteristic migraine symptoms include nausea, emesis, phonophobia, photophobia and in - 20 - 30% of migraine cases, neurologic disturbances associated with the aura phase. Although selective serotonin (5-HT) receptor agonists (i.e., 5-HT1B/1D) are successful in alleviating migrainous symptoms in ≤ 70% of known sufferers, for the remaining 30%, additional migraine abortive medications remain unsuccessful, not tested or yet to be identified. Genetic characterization of the migrainous disorder is making steady progress with an increasing number of genomic susceptibility loci now identified on chromosomes 1q, 4q, 5q, 6p, 11q, 14q, 15q, 17p, 18q, 19p and Xq. The 4q, 5q, 17p and 18q loci involve endophenotypic susceptibility regions for various migrainous symptoms. In an effort to develop individualized pharmacotherapeutics, the identification of these migraine endophenotypic loci may well be the catalyst needed to aid in this goal. In this review the authors discuss the present treatment of migraine, known genomic susceptibility regions and results from migraine (genetic) association studies. The authors also discuss pharmacogenomc considerations for more individualized migraine prophylactic treatments.
KW - Association
KW - Linkage
KW - Migraine
KW - Migraine trait component
KW - Pharmacogenomic
UR - http://www.scopus.com/inward/record.url?scp=34548283972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548283972&partnerID=8YFLogxK
U2 - 10.1517/14656566.8.12.1821
DO - 10.1517/14656566.8.12.1821
M3 - Review article
C2 - 17696786
AN - SCOPUS:34548283972
VL - 8
SP - 1821
EP - 1835
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 12
ER -